SAN DIEGO, March 11, 2009 (GLOBE NEWSWIRE) -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has initiated an international clinical study which is designed to demonstrate the efficacy of the TearLab(tm) Osmolarity System as a practical tool for the diagnosis and assessment of severity of Dry Eye Disease (DED) by measuring the osmolarity of tears. Osmolarity, simply stated, is a measure of the concentration of particles or solute per liter of solution.
